<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorder</z:e> associated with devastating microvascular complications </plain></SENT>
<SENT sid="1" pm="."><plain>Genome-wide association studies have identified more than 60 genetic variants associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and/or <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin traits, but their role in the progression of <z:mp ids='MP_0002055'>diabetes</z:mp> is not established </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to explore whether these variants were also associated with the development of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We studied 28 genetic variants in 2,229 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> from the local Malmö Scania <z:mp ids='MP_0002055'>Diabetes</z:mp> Registry (SDR) published during 2007-2010 </plain></SENT>
<SENT sid="4" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (DN) was defined as micro- or macroalbuminuria and/or <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Estimated glomerular filtration rate (eGFR) was assessed using the MDRD-4 formula </plain></SENT>
<SENT sid="6" pm="."><plain>Replication genotyping of rs1531343 was performed in diabetic (Steno type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> [n = 345], Genetics of <z:mp ids='MP_0002055'>Diabetes</z:mp> Audit and Research in Tayside Scotland [Go-DARTS] [n = 784]) and non-diabetic (Malmö Preventive Project [n = 2,523], Botnia study [n = 2,247]) cohorts </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In the SDR, HMGA2 single-nucleotide polymorphism rs1531343 was associated with DN (OR 1.50, 95% CI 1.20, 1.87, p = 0.00035) </plain></SENT>
<SENT sid="8" pm="."><plain>In the combined analysis totalling 3,358 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 1,233 cases, n = 2,125 controls), carriers of the C-allele had a 1.45-fold increased risk of developing <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (95% CI 1.20, 1.75, p = 0.00010) </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, the risk C-allele was associated with lower eGFR in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 2,499, β ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, -3.7 ± 1.2 ml/min, p = 0.002) and also in non-diabetic individuals (n = 17,602, β ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, -0.008 ± 0.003 ml/min (log( e )), p = 0.006) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: These data demonstrate that the HMGA2 variant seems to be associated with increased risk of developing <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and lower eGFR in both diabetic and non-diabetic individuals and could thus be a common denominator in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and kidney complications </plain></SENT>
</text></document>